Gyurkocza, B., Nath, R., Seropian, S., Choe, H., Litzow, M. R., Abboud, C., Koshy, N., Stiff, P., Tomlinson, B., Abhyankar, S., Foran, J., Hari, P., Chen, G., Al-Kadhimi, Z., Kebriaei, P., Sabloff, M., Orozco, J. J., Jamieson, K., Silverman, M., Besien, K. V., Schuster, M., Law, A. D., Larkin, K., Pandit-Taskar, N., Rowley, S. D., Munshi, P., Cook, R., Levy, M. Y., Lazarus, H. M., Sandmaier, B. M., Pagel, J. M., Reddy, V., MacDougall, J., McNamara, K., Spross, J., Haeuber, E., Vusirikala, M., Nahar, A., Desai, A., Giralt, S. (2025). Randomized Phase III SIERRA Trial of
            <sup>131</sup>
            I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02018